Oncocyte Q1 revenue down 41% to $176K; operating loss $9.3M; Bio-Rad partnership

Insight Molecular Diagnostics Inc.

2024-Q1 EPS reported -$1.13 revenue$176,000

Net revenue $176K, down 41% YoY; operating loss $9.3M (incl. $3.3M contingent consideration loss) vs income $5.9M in Q1 2023.
Cash burn reduced to $3.9M in Q1; management targets average quarterly burn below $5M.
Announced global commercialization partnership with Bio-Rad; Bio-Rad also bought 8.99% stake via $15.8M equity private placement.
On track to ship RUO GraftAssure kits to initial customers in Asia, US, and EU during Q2 2024; IVD kit under development for FDA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Insight Molecular Diagnostics Inc. reported the quarter ended March 31, 2024 results: revenue $176,000.

Period: the quarter ended March 31, 2024
Revenue: $176,000
Result: reported results

Exact text from the filing

Net revenue for the three months ended March 31, 2024 was $176,000, a decrease of 41% compared to the same period in 2023, due to decreased revenue from our Pharma Services business.

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.